Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2009

Cerenis Receives $3.2M to Support Development of HDL Products

Cerenis Receives $3.2M to Support Development of HDL Products

Cerenis receives $3.2 millino to develop CER-001

  • Cerenis Therapeutics has received a €2.5 million, or approximately $3.2 million, investment to finance its pipeline of HDL-related products for the treatment of cardiovascular and metabolic diseases.

    The financing will support continued development of the company's CER-001 program (recombinant HDL), which is currently in preclinical studies.

    The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies.

    In 2008, the company initiated preclinical studies to enable an IND application for this product candidate. "This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development," says Jean-Louis Dasseux, Ph.D., president and CEO of Cerenis. "We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market."ADNFCR-2184-ID-19019095-ADNFCR

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »